scholarly journals O035 / #470: 24-HOUR PRETREATMENT WITH HIGH DOSE (0.5MG/KG/DOSE) VERSUS LOW DOSE (0.25MG/KG/DOSE) DEXAMETHASONE FOR PREVENTION OF POST-EXTUBATION AIRWAY OBSTRUCTION IN CHILDREN: A RANDOMIZED OPEN-LABEL TRIAL

2021 ◽  
Vol 22 (Supplement 1 3S) ◽  
pp. 21-21
Author(s):  
A. Baranwal ◽  
B. Parajuli ◽  
P. Kumar-M ◽  
M. Jayashree
Keyword(s):  
Airway Obstruction ◽  
Low Dose ◽  
High Dose ◽  
Open Label ◽  
Open Label Trial

Open Label Trial of Add on Lacosamide Versus High Dose Levetiracetam Monotherapy in Patients With Breakthrough Seizures

2016 ◽  
Vol 39 (3) ◽  
pp. 128-131 ◽  
Author(s):  
Jong Woo Lee ◽  
Javad Alam ◽  
Nichelle Llewellyn ◽  
Shelley Hurwitz ◽  
Ellen B. Bubrick ◽  
...  
Keyword(s):  
High Dose ◽  
Open Label ◽  
Open Label Trial

Open-Label Trial of High-Dose Intravenous Immunoglobulin in Patients with Severe Asthma

2002 ◽  
Vol 15 (4) ◽  
pp. 187-194 ◽  
Author(s):  
Sandra J. Downes ◽  
Jon E. Stahlman ◽  
Irene M. Borras ◽  
Luis M. Salmun ◽  
Lynda C. Schneider
Keyword(s):  
Intravenous Immunoglobulin ◽  
Severe Asthma ◽  
High Dose ◽  
Open Label ◽  
Open Label Trial

An Open Label Trial of Low-Dose Naltrexone (LDN) for Symptomatic Mesenteric Panniculitis Presidential Poster

2015 ◽  
Vol 110 ◽  
pp. S434-S435
Author(s):  
Constantine Melitas ◽  
Grigory Roginsky ◽  
Aimee Alexoff ◽  
Eli D. Ehrenpreis
Keyword(s):  
Low Dose ◽  
Mesenteric Panniculitis ◽  
Open Label ◽  
Open Label Trial ◽  
Low Dose Naltrexone

Efficacy of Low-Dose Alteplase for Treatment of Hemodialysis Catheter Occlusions

2005 ◽  
Vol 6 (2) ◽  
pp. 76-82 ◽  
Author(s):  
J. Haymond ◽  
K. Shalansky ◽  
J. Jastrzebski
Keyword(s):  
Cost Reduction ◽  
Primary Outcome ◽  
Low Dose ◽  
Financial Analysis ◽  
Blood Flow Rate ◽  
Venous Catheter ◽  
Open Label ◽  
Hemodialysis Catheter ◽  
Catheter Patency ◽  
Open Label Trial

Background Traditionally, alteplase 2 mg/lumen doses have been used to treat central venous catheter (CVC) occlusions. On January 20, 2004, our hemodialysis (HD) unit implemented a new protocol to utilize alteplase 1 mg/lumen doses for catheter occlusion. Objectives The objectives were to 1) assess the efficacy of low-dose alteplase in restoring HD catheter patency; 2) determine the duration of CVC patency as determined by need for further alteplase doses, or radiological or surgical line interventions; and 3) evaluate the financial implications of the new protocol. Methods The study was a prospective, open-label trial of 50 consecutive HD patients with permanent, tunnelled CVC lines. A treatment course consisted of 1 or 2 doses of alteplase instilled for 60 minutes then aspirated or as an overnight (48–72 hour) dwell until the next HD. The patient's first alteplase dose following implementation of the new protocol was evaluated. Patients were followed for two months to record need for further alteplase treatment courses, and four months to document radiological or surgical line interventions. The primary outcome was to assess successful restoration of catheter patency defined as the ability of alteplase to restore or maintain HD blood flow rate at or above 300 mL/minute. A financial analysis compared alteplase costs for 11 months prior to and after implementation of the new protocol. Results Alteplase 1 mg/lumen doses restored catheter patency in 72% of HD patients with one dose, increasing to 83% with a second dose. Sixty-two percent of patients required a subsequent alteplase course with a median time to next treatment of 14 days and a median of 2 courses/patient. Radiological interventions were ordered in 38% of patients resulting in 8 lines replacements and 7 line strippings. Financial savings with the new low-dose protocol were ~CDN$22,000. Conclusion Low dose alteplase 1 mg/lumen successfully treated occlusion of permanent hemodialysis catheters, with a resulting cost reduction.

scholarly journals Low-dose ritonavir-boosted darunavir in virologically suppressed HIV-1-infected adults: an open-label trial (ANRS 165 Darulight)

2018 ◽  
Vol 73 (8) ◽  
pp. 2129-2136 ◽  
Author(s):  
Jean-Michel Molina ◽  
Sebastien Gallien ◽  
Marie-Laure Chaix ◽  
El Mountacer El Abbassi ◽  
Isabelle Madelaine ◽  
...  
Keyword(s):  
Low Dose ◽  
Open Label ◽  
Open Label Trial ◽  
Hiv 1

scholarly journals Effect of high versus low dose of dexamethasone on clinical worsening in patients hospitalised with moderate or severe COVID-19 Pneumonia: an open-label, randomised clinical trial

2021 ◽  
pp. 2102518
Author(s):  
Manuel Taboada ◽  
Nuria Rodríguez ◽  
Pablo Manuel Varela ◽  
María Teresa Rodríguez ◽  
Romina Abelleira ◽  
...  
Keyword(s):  
Dose Group ◽  
Oxygen Therapy ◽  
Low Dose ◽  
Ordinal Scale ◽  
High Dose Group ◽  
High Dose ◽  
Open Label ◽  
Once Daily ◽  
Significant Difference ◽  
Clinical Worsening

BackgroundLow dose dexamethasone demonstrated clinical improvement in patients with coronavirus disease 2019 (COVID-19) needing oxygen therapy; however, evidence on the efficacy of high dose of dexamethasone is limited.MethodsWe performed a randomised, open-label, controlled trial involving hospitalised patients with confirmed COVID-19 pneumonia needing oxygen therapy. Patients were randomly assigned in a 1:1 ratio to receive low dose dexamethasone (6 mg once daily for 10 days) or high dose dexamethasone (20 mg once daily for 5 days, followed by 10 mg once daily for additional 5 days). The primary outcome was clinical worsening within 11 days since randomisation. Secondary outcomes included 28-day mortality, time to recovery, and clinical status at day 5, 11, 14 and 28 on an ordinal scale ranging from 1 (discharged) to 7 (death).ResultsA total of 200 patients (mean (sd) age, 64 (14) years; 62% male) were enrolled. Thirty-two patients of 102 (31.4%) enrolled in the low dose group and 16 of 98 (16.3%) in the high dose group showed clinical worsening within 11 days since randomisation (rate ratio, 0.427; 95% CI, 0.216–0.842; p=0.014). The 28-day mortality was 5.9% in the low dose group and 6.1% in the high dose group (p=0.844). There was no significant difference in time to recovery, and in the 7-point ordinal scale at day 5, 11, 14 and 28.ConclusionsAmong hospitalised COVID-19 patients needing oxygen therapy, high dose of dexamethasone reduced clinical worsening within 11 days after randomisation as compared with low dose.

Preliminary investigation of high-dose oral glycine on serum levels and negative symptoms in schizophrenia: an open-label trial

1996 ◽  
Vol 39 (3) ◽  
pp. 213-215 ◽  
Author(s):  
Eduardo Leiderman ◽  
Ilana Zylberman ◽  
Stephen R. Zukin ◽  
Thomas B. Cooper ◽  
Daniel C. Javitt
Keyword(s):  
Negative Symptoms ◽  
Preliminary Investigation ◽  
Serum Levels ◽  
High Dose ◽  
Open Label ◽  
Dose Oral ◽  
Open Label Trial
Sign in / Sign up

Export Citation Format

Share Document